- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04969367
Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome
August 14, 2023 updated by: Thomas Jefferson University
Measuring Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome (MDS)
This study assesses feasibility and patient acceptability of using a Fitbit to monitor step count and heart rate in transfusion dependent patients with myelodysplastic syndrome.
Information from this study may help researchers understand if there is any correlation between activity level and anemia.
Study Overview
Status
Withdrawn
Conditions
Detailed Description
This study assesses feasibility and patient acceptability of using a Fitbit to monitor step count and heart rate in transfusion dependent patients with myelodysplastic syndrome.
Information from this study may help researchers understand if there is any correlation between activity level and anemia.
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Sidney Kimmel Cancer Center at Thomas Jefferson University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with myelodysplastic syndrome (MDS) recruited from the Department of Medical Oncology- Jefferson Health
Description
Inclusion Criteria:
- Confirmed pathologic diagnosis of MDS
- Requiring >= 2 blood transfusions in the past month if previously diagnosed or hemoglobin =< 8 g/dL if newly diagnosed
- Age >= 18
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Ambulatory (use of a walking aid, such as a cane or rollator, is acceptable)
- Able to give informed consent
- Willing to comply with all study procedures and available for the duration of the study
- Able to read and/or understand English
- Have access to an iPhone 4S or later, iPad 3 generation or later, Android 5.0 or later, or Windows 10 device
- Have access to Bluetooth low energy (LE) and internet connection for syncing
Exclusion Criteria:
• Uncontrolled illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observational (activity monitor)
Patients wear an activity monitor (Fitbit) for 90 days.
Patients also undergo collection of blood samples and complete questionnaires twice weekly for up to 90 days.
|
Undergo collection of blood samples
Complete questionnaires
Complete questionnaires
Wear activity monitor (Fitbit)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability
Time Frame: Up to 90 days
|
Acceptability will be measured by a short survey
|
Up to 90 days
|
compliance with device
Time Frame: Up to 90 days
|
compliance with device (80% of the 90-day intervention time)
|
Up to 90 days
|
Acceptability
Time Frame: Up to 90 days
|
Acceptability will be measured by an interview addressing participant satisfaction
|
Up to 90 days
|
Accrual rate
Time Frame: Up to 90 days
|
accrual rate will be measured by counting subjects
|
Up to 90 days
|
retention rate
Time Frame: Up to 90 days
|
retention rate of subjects will be measured by counting at 90 days
|
Up to 90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily step count
Time Frame: Up to 90 days
|
Daily step count
|
Up to 90 days
|
Average daily resting heart rate
Time Frame: Up to 90 days
|
average daily resting heart rate
|
Up to 90 days
|
Fact-An score (assessed twice a week),
Time Frame: Up to 90 days
|
Fact-An score (assessed twice a week),
|
Up to 90 days
|
Hemoglobin level measured by CBC twice a week
Time Frame: Up to 90 days
|
Hemoglobin level measured by CBC twice a week
|
Up to 90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 10, 2021
Primary Completion (Actual)
July 19, 2023
Study Completion (Actual)
July 19, 2023
Study Registration Dates
First Submitted
July 6, 2021
First Submitted That Met QC Criteria
July 19, 2021
First Posted (Actual)
July 20, 2021
Study Record Updates
Last Update Posted (Actual)
August 18, 2023
Last Update Submitted That Met QC Criteria
August 14, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21D.214
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
Clinical Trials on Biospecimen Collection
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingBreast Adenocarcinoma | HER2-Positive Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States, Puerto Rico
-
LLS PedAL Initiative, LLCNational Cancer Institute (NCI); Children's Oncology GroupRecruitingAcute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Myeloid Leukemia Associated With Down Syndrome | Mixed Phenotype Acute Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy | Myelodysplastic Syndrome Post Cytotoxic TherapyUnited States, Canada, Australia, Puerto Rico, New Zealand
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)Active, not recruiting
-
Mayo ClinicRecruitingEarly Stage Breast Carcinoma | Chemotherapy-Related Nausea and/or VomitingUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruiting
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8United States
-
Ohio State University Comprehensive Cancer CenterGuardant Health, Inc.RecruitingColorectal CarcinomaUnited States
-
M.D. Anderson Cancer CenterRecruitingCholangiocarcinoma | Malignant Digestive System NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Recruiting